PE anti-mouse IL-2 Antibody

Pricing & Availability
Clone
JES6-5H4 (See other available formats)
Regulatory Status
RUO
Other Names
Interleukin-2, T cell growth factor (TCGF), Eosinophil differentiation factor (EDF), Killer cell helper factor (KHF), Macrophage-activating factor for cytotoxicity I (MAF-C I), Thymocyte differentiation factor (TDF)
Isotype
Rat IgG2b, κ
JES6-5H4_PE_011108
PMA+ionomycin-stimulated C57BL/6 mouse splenocytes intracellular stained with with CD3 (17A2) APC and JES6-5H4 PE
  • JES6-5H4_PE_011108
    PMA+ionomycin-stimulated C57BL/6 mouse splenocytes intracellular stained with with CD3 (17A2) APC and JES6-5H4 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability
503807 25 µg $83.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
503808 100 µg $220.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

IL-2 is a potent lymphoid cell growth factor which exerts its biological activity primarily on T cells. Additionally, IL-2 has been found to stimulate growth and differentiation of B cells, NK cells, LAK cells, monocytes, and oligodendrocytes.

Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
E. coli-expressed, recombinant mouse IL-2
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

ELISA Detection1-3 or ELISPOT Detection4-6: The biotinylated JES6-5H4 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with the purified JES6-1A12 antibody (Cat. Nos. 503701 & 503702) as capture antibody and recombinant mouse IL-2 (Cat. No. 575409) as the standard.
Flow Cytometry8-10: The fluorochrome-labeled JES6-5H4 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IL-2 -producing cells within mixed cell populations.
Neutralization1,7: The Ultra-LEAF™ purified antibody (Endotoxin in vivo and in vitro (Cat. No. 503845-503850)) is recommended for neutralization.
Additional reported applications (for the relevant formats) include: immunoprecipitation1, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated frozen tissue sections2, in vivo capture7, and immunocytochemistry.
Note: For testing mouse IL-2 in serum, plasma or supernatant, BioLegend's ELISA MAX™ Sets (Cat. No. 431001 & 431004) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Abrams J, et al. 1992. Immunol. Rev. 127:5.
  2. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
  3. Abrams J. 1995. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.20.
  4. Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons New York. Unit 6.19.
  5. Mo X, et al. 1995. J. Virol. 69:1288.
  6. Karulin A, et al. 2000. J. Immunol. 164:1862.
  7. Finkelman F, et al. 2003. Curr. Prot. Immunol. John Wiley & Sons New York. Unit 6.28.
  8. Ko SY, et al. 2005. J. Immunol. 175:3309. PubMed
  9. Kang SS and Allen PM. 2005. J. Immunol. 174:5382.
  10. Lawson BR, et al. 2007. J. Immunol. 178:5366.
Product Citations
  1. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  2. D'Angeli V, et al. 2022. Eur J Immunol. 52:1058. PubMed
  3. Dölz M, et al. 2022. iScience. 25:105372. PubMed
  4. Nanishi E, et al. 2023. NPJ Vaccines. 8:18. PubMed
  5. Hirai T, et al. 2020. Immunity. 54(1):84-98.e5. PubMed
  6. Elong Ngono A, et al. 2020. Cell Reports. 1.330555556. PubMed
  7. Shi X, et al. 2023. iScience. 26:106143. PubMed
  8. van Elsas MJ, et al. 2023. J Immunother Cancer. 11:. PubMed
  9. Seo YB, et al. 2023. Int J Mol Sci. 24:. PubMed
  10. Wilfahrt D, et al. 2021. Elife. 10:. PubMed
  11. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  12. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  13. Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed
  14. Page N, et al. 2018. Immunity. 48:937. PubMed
  15. Wei H, et al. 2021. Malar J. 20:89. PubMed
  16. Seo YB, et al. 2021. Vaccines (Basel). 9: . PubMed
  17. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  18. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  19. Maschmeyer P, et al. 2017. J Autoimmun.. 10.1016/j.jaut.2017.11.005. PubMed
  20. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  21. Liang Y, et al. 2020. J Immunol. 204:2984. PubMed
  22. Klarquist J, et al. 2021. Cell Rep. 36:109591. PubMed
  23. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
  24. Oda SK, et al. 2020. J Exp Med. 217: . PubMed
  25. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
  26. Tanaka Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  27. Shrivastava T, et al. 2021. Front Immunol. 12:641447. PubMed
  28. Marangoni F, et al. 2021. Cell. . PubMed
  29. Zhuang Z, et al. 2021. J Exp Med. 218:00:00. PubMed
  30. Lercher A, et al. 2019. Immunity. 51:1074. PubMed
  31. Dolina JS, et al. 2020. Cell Rep. 107249:31. PubMed
  32. Chang Q, et al. 2020. Scand J Immunol. 92:e12877. PubMed
  33. Kelsey E Sivick et al. 2018. Cell reports. 25(11):3074-3085 . PubMed
  34. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  35. Grigoryan L, et al. 2022. NPJ Vaccines. 7:55. PubMed
  36. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  37. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  38. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  39. Knocke S, et al. 2016. Cell Rep. 17:2234-2246. PubMed
  40. White C, et al. 2015. J Immunol. 194:697. PubMed
  41. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  42. Ye X, et al. 2021. Cancer Biol Med. Online ahead of print. PubMed
  43. Yan J, et al. 2020. Cell Rep. 107820:31. PubMed
  44. Kim MY, et al. 2017. Plant Biotechnol J. 1.729166667. PubMed
  45. Ma K, et al. 2022. iScience. 25:104347. PubMed
  46. Evgin L, et al. 2022. Sci Transl Med. 14:eabn2231. PubMed
  47. Toshiro Hirai et al. 2019. Immunity. 50(5):1249-1261 . PubMed
  48. Majedi FS, et al. 2020. Biomaterials. 252:120058. PubMed
  49. Varikuti S, et al. 2020. Br J Cancer. 122:1005. PubMed
  50. Yan Q, et al. 2017. Molecular Immunology. 10.1016/j.molimm.2017.05.006. PubMed
  51. Wen J, et al. 2020. Cell Rep. 31:107566. PubMed
  52. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  53. Kung YJ, et al. 2022. J Biomed Sci. 29:57. PubMed
  54. Nanishi E, et al. 2022. Commun Biol. 5:790. PubMed
  55. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  56. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  57. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
  58. Haring J, et al. 2008. J Immunol. 180:2855. PubMed
  59. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  60. Reguzova A, et al. 2020. Vaccines (Basel). 8:. PubMed
  61. Li J, et al. 2021. Cell Reports. 34(11):108839. PubMed
  62. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  63. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  64. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
  65. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  66. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  67. Liu Z, et al. 2022. Int J Nanomedicine. 17:1711. PubMed
  68. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
RRID
AB_315301 (BioLegend Cat. No. 503807)
AB_315301 (BioLegend Cat. No. 503808)

Antigen Details

Structure
Cytokine; 15-30 kD (Mammalian)
Bioactivity
Proliferation of T lymphocytes, B cells, anti-inflammatory, hematopoiesis, tumor surveillance
Cell Sources
T cells
Cell Targets
T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
Receptors
High affinity heterotrimer of IL-2Rα/β/γ, intermediate affinity homodimer IL-2Rα (CD25; p55; Tac) and heterodimer IL-2Rβ (CD122)/γ; γ-subunit (CD132) in common with IL-4R, IL-7R, IL-13R, IL-15R
Cell Type
Tregs
Biology Area
Immunology
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego.
2. Taniguchi T, et al. 1993. Cell 73:5.
3. Nistico G. 1993. Prog. Neurobiol. 40:463.
4. Waldmann T, et al. 1993. Ann. NY Acad. Sci. 685:603.

Regulation
Upregulated by NFAT; downregulated by TCF-8, CIF (colostrum inhibitory factor)
Gene ID
16183 View all products for this Gene ID
UniProt
View information about IL-2 on UniProt.org
Go To Top Version: 1    Revision Date: 11/30/2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Login/Register
Forgot your password? Reset Password
Request an Account